Novo Nordisk has launched its blockbuster Wegovy weight-loss drug in China, adding the world’s second-largest economy to its growing list of markets where appetite for the drugs are rising.The first prescription for Wegovy in China will be issued at a public hospital in Shanghai this week and will cost about 1,

Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound. The goal of the hourlong meeting with association leaders was to cement one core message: Obesity care is healthcare.

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help unemployed people re-enter the workforce and ultimately save money on health care.

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.

Popular semaglutide-based drugs used for weight loss may reduce chronic and acute pain, which could make them a promising alternative to opioids

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, rates of bariatric surgeries dropped by 25%, while prescriptions for weight-loss drugs more than doubled.

Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it against rival Eli Lilly, whose treatment, Zepbound, is yet to hit shelves in the world's second-largest pharmaceutical market.